BM331

BM331 is an investigational oncology drug candidate developed by Biomissile. It is designed as a tumor microenvironment (TME) modulator, a therapeutic approach that aims to alter the biochemical and cellular conditions within a tumor to overcome immunosuppression and enhance the effectiveness of the immune system against cancer cells. BM331 is part of Biomissile's pipeline of next-generation biologics, which includes immune cell engagers and other TME-targeting agents. While the specific molecular target of BM331 has not been publicly disclosed, it is being developed for the treatment of various cancers by reprogramming the TME to facilitate more effective anti-tumor immune activity.